



EMA/435864/2018 Rev. 1

**Update of 23 June 2020:**

The shortage affecting Cinryze has been resolved and the below information and recommendations which were issued during the shortage no longer apply.

3 August 2018

### Shortage of Cinryze (C1 inhibitor, human) powder and solvent for intravenous injection

<b>Indication</b>	<p>Cinryze is a medicine used to treat angioedema (swelling) attacks in adults and adolescents aged 12 to 17 years with hereditary angioedema.</p> <p>Cinryze is also used for the prevention of angioedema attacks that can be triggered by medical, dental or surgical procedures.</p> <p>Cinryze is also used for routine prevention in patients who have severe and frequent angioedema attacks for which prevention with oral medicines is not adequate or in patients whose attacks are not adequately treated.</p>
<b>Reason for shortage</b>	<p>The manufacturer is facing a new increase in demand for Cinryze which outweighs current production capacities. While the manufacturer is adjusting production capacity, temporary treatment recommendations are in place to manage existing stocks.</p>
<b>Member States affected<sup>1</sup></b>	<p>The EU Member States that may be impacted by a potential shortage are: Austria, Denmark, France, Germany, Ireland, Italy, Spain, Sweden, United Kingdom, as well as Iceland and Norway.</p>
<b>Information for healthcare professionals</b>	<ul style="list-style-type: none"><li>• An increased demand for Cinryze may result in a temporary supply shortage while the manufacturer is adjusting production capacity.</li><li>• Healthcare professionals have been informed in writing about the potential supply problem.</li><li>• In order to manage existing stocks, prescribers should</li></ul>

<sup>1</sup> This information may change. For up-to-date information about the status of a medicine shortage in a particular Member State, contact the [national competent authority](#).



## Shortage of Cinryze (C1 inhibitor, human) powder and solvent for intravenous injection

	<p>consider alternative treatment options for patients who require treatment and pre-procedure prevention of angioedema attacks.</p> <ul style="list-style-type: none"><li>• When used for routine prevention of angioedema attacks patients who are already receiving Cinryze may continue to receive Cinryze.</li><li>• Consider not starting new patients for routine prevention.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li></ul>
<b>Information for patients</b>	<ul style="list-style-type: none"><li>• An increased demand for Cinryze may result in a temporary supply shortage while the manufacturer is adjusting production capacity.</li><li>• To manage stocks efficiently, doctors will consider alternative treatment when using Cinryze for treatment of angioedema attacks and prevention before medical, dental or surgical procedures.</li><li>• When used for routine prevention of angioedema attacks patients already on treatment may continue to receive Cinryze.</li><li>• Patients who have any questions should speak to their doctor or pharmacist.</li><li>• Additional advice may be available from the <a href="#">national competent authority</a>.</li></ul>